These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The effect of antibody against vascular endothelial growth factor on tumor growth].
    Author: Wang G, Wang N, Liu T.
    Journal: Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):163-6. PubMed ID: 10920886.
    Abstract:
    OBJECTIVE: Vascular endothelial growth factor (VEGF) is a very important factor in the process of angiogenesis, which is chosen as a target for experimental study of anticancer. METHODS: Anti-VEGF antibody was obtained from immunized rabbits and purified with affinity column. Morever, it was identified as neutralized antibody by Mile's assay. RESULTS: The anti-VEGF antibody was able to inhibit growth of S180 sarcoma in a dose-dependent manner, and the inhibition rate reached 41.0% with dose 200 micrograms per mouse per day. For human gastric cancer (MGC-803)-bearing nude mice, Anti-VEGF antibody inhibited tumor growth by 76.2%. When anti-VEGF antibody was combined with 131I-3H11, a murine monoclonal antibody conjugated with 131I for treatment, only one of five nude mice developed tumor and 84.0% more inhibition of tumor growth was obtained in comparison with treatment by 131I-3H11 only. CONCLUSION: The anti-VEGF antibody may be potentially useful for clinical treatment of cancer.
    [Abstract] [Full Text] [Related] [New Search]